Metastatic Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Double-Blind, Phase 3 Study of MK-7684A in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer
| Verified date | January 2024 |
| Source | Merck Sharp & Dohme LLC |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in treatment-naïve metastatic participants with non-small cell lung cancer (NSCLC).
| Status | Active, not recruiting |
| Enrollment | 700 |
| Est. completion date | September 27, 2027 |
| Est. primary completion date | November 10, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: - A histologically or cytologically confirmed diagnosis of Stage IV squamous or non-squamous NSCLC. - Has not received prior systemic treatment for metastatic NSCLC. - Has measurable disease based on RECIST 1.1, as determined by the local site assessment. - Has a life expectancy of at least 3 months. - Males: Use contraception unless confirmed to be azoospermic; Females: Women of childbearing potential use highly effective contraceptive method. Exclusion Criteria: - Known additional malignancy that is progressing or has required active treatment within the past 3 years. - Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. - Severe hypersensitivity to vibostolimab, pembrolizumab, chemotherapy components, and/or any of its excipients. - Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study medication. - Active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. - History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. - Has an active infection requiring systemic therapy. - Has a known history of human immunodeficiency virus (HIV), Hepatitis B or/and Hepatitis C virus. - Received prior systemic anticancer therapy for metastatic disease. - Received a live or live attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. - History of allogeneic tissue/solid organ transplant. - Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose =1.3 g/day, for a 5-day period (8-day period for long-acting agents, such as piroxicam). - Is unable or unwilling to take folic acid or vitamin B12 supplementation. - Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention. |
| Country | Name | City | State |
|---|---|---|---|
| Argentina | Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0209) | ABB | Caba |
| Argentina | Centro de Oncología e Investigación de Buenos Aires ( Site 0203) | Berazategui | Buenos Aires |
| Argentina | Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Medical Oncology ( Site 0202) | Buenos Aires | Caba |
| Argentina | Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0206) | La Rioja | |
| Argentina | Instituto de Investigaciones Clínicas Mar del Plata ( Site 0204) | Mar del Plata | Buenos Aires |
| Argentina | Hospital Provincial del Centenario ( Site 0212) | Rosario | Santa Fe |
| Argentina | Sanatorio Parque ( Site 0205) | Rosario | Santa Fe |
| Austria | Medizinische Universität Graz ( Site 0704) | Graz | Steiermark |
| Austria | Medizinische Universitaet Innsbruck ( Site 0703) | Innsbruck | Tirol |
| Austria | Kepler Universitätsklinikum ( Site 0707) | Linz | Oberosterreich |
| Austria | Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0705) | Linz | Oberosterreich |
| Austria | Klinik Penzing-2. Lungenabteilung ( Site 0702) | Vienna | Wien |
| Austria | Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0701) | Wien | |
| Brazil | Clínica de Oncologia Reichow ( Site 0407) | Blumenau | Santa Catarina |
| Brazil | Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0403) | Natal | Rio Grande Do Norte |
| Brazil | Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0405) | Porto Alegre | Rio Grande Do Sul |
| Brazil | Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA ( Site 0406) | Rio de Janeiro | |
| Brazil | Hospital Paulistano ( Site 0401) | Sao Paulo | |
| Chile | Centro de Investigación Oncológica del Norte ( Site 0504) | Antofagasta | |
| Chile | Biocenter ( Site 0514) | Concepción | Biobio |
| Chile | Bradfordhill ( Site 0510) | Santiago | Region M. De Santiago |
| Chile | Centro de Oncología de Precisión ( Site 0515) | Santiago | Region M. De Santiago |
| Chile | FALP-UIDO ( Site 0505) | Santiago | Region M. De Santiago |
| Chile | CIDO SpA-Oncology ( Site 0508) | Temuco | Araucania |
| Chile | James Lind Centro de Investigación del Cáncer ( Site 0502) | Temuco | Araucania |
| Chile | ONCOCENTRO APYS-ACEREY ( Site 0503) | Viña del Mar | Valparaiso |
| China | Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2602) | Beijing | Beijing |
| China | Jilin Cancer Hospital-oncology department ( Site 2603) | Changchun | Jilin |
| China | Hunan Cancer Hospital ( Site 2622) | Changsha | Hunan |
| China | The Second Xiangya Hospital of Central South University ( Site 2623) | Changsha | Hunan |
| China | Xiangya Hospital Central South University-Oncology department ( Site 2627) | Changsha | Hunan |
| China | West China Hospital of Sichuan University ( Site 2610) | Cheng Du | Sichuan |
| China | Sichuan Cancer hospital ( Site 2628) | Chengdu | Sichuan |
| China | Fujian Provincial Cancer Hospital-oncology department ( Site 2621) | Fuzhou | Fujian |
| China | Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( | Guangzhou | Guangdong |
| China | Sir Run Run Shaw Hospital-Medical Oncology ( Site 2615) | Hangzhou | Zhejiang |
| China | The First Affiliated Hospital, Zhejiang University-Respiratory Department ( Site 2613) | Hangzhou | Zhejiang |
| China | The Second Affiliated hospital of Zhejiang University school of medicine-Respiratory Medicine ( Site | Hangzhou | Zhejiang |
| China | Zhejiang Cancer Hospital-Oncology ( Site 2612) | Hangzhou | Zhejiang |
| China | Harbin Medical University Cancer Hospital-oncology of department ( Site 2604) | Harbin | Heilongjiang |
| China | Anhui Provincil Hospital South District-Respiratory Medicine Dept ( Site 2619) | Hefei | Anhui |
| China | Shandong Cancer Hospital-Oncology Department ( Site 2630) | Jinan | Shandong |
| China | The First Affiliated Hospital of Nanchang University-Respiratory Medicine Department ( Site 2625) | Nanchang | Jiangxi |
| China | The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 2624) | Nanchang | Jiangxi |
| China | Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology ( | Nanjing | Jiangsu |
| China | Fudan University Shanghai Cancer Center ( Site 2616) | Shanghai | Shanghai |
| China | Shanghai Pulmonary Hospital-Oncology Department ( Site 2601) | Shanghai | Shanghai |
| China | Tianjin Medical University Cancer Institute and Hospital-lung cancer ( Site 2606) | Tianjin | Tianjin |
| China | Tongji Hospital Tongji Medical,Science & Technology ( Site 2617) | Wuhan | Hubei |
| China | Wuhan Union Hospital Cancer Center-Cancer Center ( Site 2618) | Wuhan | Hubei |
| China | The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 2607) | Xi'an | Shaanxi |
| China | The First Affiliated hospital of Xiamen University ( Site 2626) | Xiamen City | Fujian |
| China | The Second People's Hospital of Yibin ( Site 2629) | Yibin | Sichuan |
| China | Henan Cancer Hospital ( Site 2608) | Zhengzhou | Henan |
| Colombia | Administradora Country S.A. - Clinica del Country ( Site 0601) | Bogotá | Distrito Capital De Bogota |
| Colombia | Fundación Colombiana de Cancerología Clínica Vida ( Site 0603) | Medellin | Antioquia |
| Colombia | Oncomedica S.A.-Oncomedica S.A ( Site 0609) | Montería | Cordoba |
| Colombia | Oncologos del Occidente ( Site 0608) | Pereira | Risaralda |
| Colombia | Sociedad De Oncologia Y Hematologia Del Cesar ( Site 0606) | Valledupar | Cesar |
| France | Institut de Cancérologie de l'Ouest ( Site 0802) | ANGERS cedex 02 | Maine-et-Loire |
| France | Centre Hospitalier d'Avignon ( Site 0810) | Avignon | Vaucluse |
| France | Centre Hospitalier d'Annecy ( Site 0807) | Epagny Metz-Tessy | Haute-Savoie |
| France | Centre Hospitalier Regional Universitaire de Lille - Hôpital-Service de pneumologie et oncologie th | Lille | Nord-Pas-de-Calais |
| France | CENTRE LEON BERARD ( Site 0803) | Lyon CEDEX 08 | Rhone |
| France | CENTRE HOSPITALIER REGIONAL D'ORLEANS-Service de Pneumologie ( Site 0806) | Orléans | Centre |
| France | HIA Sainte Anne ( Site 0804) | Toulon | Var |
| Germany | Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 0913 | Berlin | |
| Germany | GEFOS Gesellschaft f. onkologische Studien ( Site 0909) | Dortmund | Nordrhein-Westfalen |
| Germany | SRH Wald-Klinikum Gera ( Site 0911) | Gera | Thuringen |
| Germany | UKGM Gießen/Marburg-Medical Clinic V ( Site 0912) | Gießen | Hessen |
| Germany | Universitätsklinikum Schleswig-Holstein-Pneumologie ( Site 0902) | Lübeck | Schleswig-Holstein |
| Israel | Rambam Health Care Campus-Oncology ( Site 1303) | Haifa | |
| Israel | Shaare Zedek Medical Center-Oncology ( Site 1306) | Jerusalem | |
| Israel | Meir Medical Center-oncology ( Site 1301) | Kfar Saba | |
| Israel | Sheba Medical Center-ONCOLOGY ( Site 1302) | Ramat Gan | |
| Israel | Sourasky Medical Center-Oncology ( Site 1305) | Tel Aviv | |
| Japan | Hyogo Cancer Center-Thoracic Oncology ( Site 2409) | Akashi | Hyogo |
| Japan | National Hospital Organization Kyushu Cancer Center ( Site 2412) | Fukuoka | |
| Japan | National Hospital Organization Kyushu Medical Center ( Site 2413) | Fukuoka | |
| Japan | Kansai Medical University Hospital ( Site 2415) | Hirakata | Osaka |
| Japan | Saitama Prefectural Cancer Center ( Site 2406) | Ina-machi | Saitama |
| Japan | Kanazawa University Hospital ( Site 2407) | Kanazawa | Ishikawa |
| Japan | Japanese Foundation for Cancer Research ( Site 2402) | Koto | Tokyo |
| Japan | National Hospital Organization Shikoku Cancer Center ( Site 2414) | Matsuyama | Ehime |
| Japan | Shizuoka Cancer Center ( Site 2408) | Nagaizumi | Shizuoka |
| Japan | Miyagi Cancer Center ( Site 2401) | Natori | Miyagi |
| Japan | Okayama University Hospital ( Site 2410) | Okayama | |
| Japan | Showa University Hospital ( Site 2403) | Shinagawa | Tokyo |
| Japan | Nippon Medical School Hospital ( Site 2404) | Tokyo | |
| Japan | Ehime University Hospital ( Site 2411) | Toon | Ehime |
| Japan | Kanagawa cancer center-Department of Thoracic Oncology ( Site 2405) | Yokohama | Kanagawa |
| Korea, Republic of | Pusan National University Hospital ( Site 2205) | Busan | Pusan-Kwangyokshi |
| Korea, Republic of | Chungnam national university hospital-Department of Internal Medicine ( Site 2203) | Daejeon | Taejon-Kwangyokshi |
| Korea, Republic of | Kyungpook National University Chilgok Hospital-Pulmonology ( Site 2202) | Deagu | Taegu-Kwangyokshi |
| Korea, Republic of | Chonnam National University Hwasun Hospital-Pulmonology ( Site 2201) | Hwasun | Jeonranamdo |
| Korea, Republic of | Korea University Guro Hospital-Internal Medicine ( Site 2204) | Seoul | |
| Korea, Republic of | Asan Medical Center ( Site 2206) | Songpa-gu | Seoul |
| Mexico | Alivia Clínica de Alta Especialidad ( Site 0310) | Ciudad de Mexico | Distrito Federal |
| Mexico | Hospital Civil Fray Antonio Alcalde ( Site 0307) | Guadalajara | Jalisco |
| Mexico | Arké SMO S.A. de C.V. ( Site 0301) | Mexico | Distrito Federal |
| Mexico | CENTRO DE INFUSION E INVESTIGACION ONCOLOGIA DE SALTILLO S.C. ( Site 0304) | Saltillo | Coahuila |
| Poland | Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1903) | Bydgoszcz | Kujawsko-pomorskie |
| Poland | Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1907) | Bystra | Slaskie |
| Poland | Przychodnia Lekarska KOMED ( Site 1902) | Konin | Wielkopolskie |
| Poland | Med-Polonia Sp. z o. o. ( Site 1909) | Poznan | Wielkopolskie |
| Poland | Szpital Specjalistyczny w Prabutach Spolka z o.o. ( Site 1906) | Prabuty | Pomorskie |
| Poland | Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1904) | Przemysl | Podkarpackie |
| Poland | Centrum Medyczne Ostrobramska NZOZ Magodent ( Site 1908) | Warsaw | Mazowieckie |
| Poland | Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier | Warszawa | Mazowieckie |
| Spain | CHUAC-Hospital Teresa Herrera-MEDICAL ONCOLOGY ( Site 1106) | A Coruña | La Coruna |
| Spain | Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101) | Barcelona | |
| Spain | Hospital Insular de Gran Canaria-Oncology ( Site 1102) | Las Palmas de Gran Canaria | Las Palmas |
| Spain | Hospital Clinico San Carlos-Oncology Department ( Site 1107) | Madrid | |
| Spain | Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1103) | Sevilla | |
| Spain | Hospital Clínico Universitario Lozano Blesa-Oncology ( Site 1105) | Zaragoza | |
| Taiwan | Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 2254) | Kaohsiung | |
| Taiwan | China Medical University Hospital ( Site 2253) | Taichung | |
| Taiwan | NATIONAL CHENG-KUNG UNI. HOSP. ( Site 2252) | Tainan | |
| Taiwan | National Taiwan University Hospital-Oncology ( Site 2255) | Taipei | |
| Taiwan | Chang Gung Medical Foundation-Linkou Branch ( Site 2251) | Taoyuan | |
| Thailand | Faculty of Medicine Siriraj Hospital ( Site 2304) | Bangkok | Krung Thep Maha Nakhon |
| Thailand | Maharaj Nakorn Chiang Mai Hospital-Chiang Mai Clinical Trial Unit (CM-CTU) ( Site 2301) | Chiang Mai | |
| Thailand | Songklanagarind hospital ( Site 2302) | Hatyai | Songkhla |
| Thailand | Chulabhorn Hospital ( Site 2305) | Lak Si | Krung Thep Maha Nakhon |
| Thailand | Faculty of Medicine - Khon Kaen University ( Site 2303) | Muang | Khon Kaen |
| Turkey | Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1208) | Adana | |
| Turkey | Ankara City Hospital ( Site 1204) | Ankara | |
| Turkey | Hacettepe Universitesi-oncology hospital ( Site 1202) | Ankara | |
| Turkey | Liv Hospital Ankara-Oncology ( Site 1205) | Ankara | |
| Turkey | Trakya University-Medical Oncology ( Site 1203) | Edirne | |
| Turkey | TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1209) | Istanbul | |
| Turkey | Umraniye Training and Research Hospital-medical oncology ( Site 1206) | Istanbul | |
| Turkey | Acibadem Altunizade Hospital-Oncology ( Site 1207) | Üsküdar / Stanbul | Istanbul |
| United Kingdom | Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 1502) | Leicester | England |
| United Kingdom | Chelsea and Westminster Hospital NHS Foundation Trust-Research and Development ( Site 1501) | London | England |
| United Kingdom | St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1506) | London | London, City Of |
| United Kingdom | University College London Hospital-Cancer Clinical Trials Unit ( Site 1509) | London-Camden | London, City Of |
| United States | Charleston Oncology ( Site 0019) | Charleston | South Carolina |
| United States | University of Virginia Cancer Center ( Site 0018) | Charlottesville | Virginia |
| United States | Mount Sinai Hospital ( Site 0011) | Chicago | Illinois |
| United States | University of Chicago Medical Center ( Site 0015) | Chicago | Illinois |
| United States | UCHealth Memorial Hospital-Heme Onc ( Site 0003) | Colorado Springs | Colorado |
| United States | University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0031) | Fort Collins | Colorado |
| United States | Cancer and Hematology Centers of Western Michigan ( Site 0002) | Grand Rapids | Michigan |
| United States | Mayo Clinic in Florida ( Site 0022) | Jacksonville | Florida |
| United States | Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0012) | Lancaster | Pennsylvania |
| United States | Mayo Clinic in Rochester, Minnesota ( Site 0030) | Rochester | Minnesota |
| United States | New England Cancer Specialists ( Site 0008) | Scarborough | Maine |
| United States | Stony Brook University-Cancer Center ( Site 0013) | Stony Brook | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Merck Sharp & Dohme LLC |
United States, Argentina, Austria, Brazil, Chile, China, Colombia, France, Germany, Israel, Japan, Korea, Republic of, Mexico, Poland, Spain, Taiwan, Thailand, Turkey, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall Survival (OS) | OS is defined as the time from randomization to the date of death due to any cause. | Up to approximately 40 months | |
| Secondary | Progression-Free Survival (PFS) | PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. | Up to approximately 40 months | |
| Secondary | Objective Response Rate (ORR) | ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented. | Up to approximately 40 months | |
| Secondary | Change from Baseline in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Change from baseline in the score of EORTC QLQ-C30 Items 29 and 30 will be presented. The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to Items 29 and 30 ("How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. | Baseline and Up to approximately 40 months | |
| Secondary | Change from Baseline in Physical Functioning (Items 1-5) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Change from baseline in the score of EORTC QLQ-C30 Items 1-5 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. | Baseline and Up to approximately 40 months | |
| Secondary | Change from Baseline for Role Functioning Combined (Items 6 and 7) Score on the EORTC QLQ-C30 | Change from baseline in the score of EORTC QLQ-C30 Items 6-7 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. | Baseline and up to approximately 40 months | |
| Secondary | Change from Baseline in Dyspnea Score (Item 8) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Change from baseline in the score of EORTC QLQ-C30 Item 8 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Were you short of breath?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of dyspnea. | Baseline and Up to approximately 40 months | |
| Secondary | Change from Baseline in Cough Score (Item 31) on the European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-LC13) | Change from baseline in the score of EORTC QLQ-C13 Item 31 will be presented. The EORTC QLQ-C13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Have you coughed?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates more frequent coughing. | Baseline and Up to approximately 40 months | |
| Secondary | Change from Baseline in Chest Pain Score (Item 40) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Change from baseline in the score of EORTC QLQ-C13 Item 40 will be presented. The EORTC QLQ-C13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Have you had pain in your chest?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of chest pain. | Baseline and Up to approximately 40 months | |
| Secondary | Time to Deterioration (TTD) in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | TTD in the score of EORTC QLQ-C30 Items 29 and 30 will be presented. The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to Items 29 and 30 ("How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 40 months | |
| Secondary | TTD in Physical Functioning (Items 1-5) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | TTD in the score of EORTC QLQ-C30 Items 1-5 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 40 months | |
| Secondary | TTD in Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30 | TTD in the score of EORTC QLQ-C30 Items 6-7 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 2 questions about their role functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a worse level of function. | Up to approximately 40 months | |
| Secondary | TTD in Dyspnea Score (Item 8) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | TTD in the score of EORTC QLQ-C30 Item 8 will be presented. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Were you short of breath?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of dyspnea. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 40 months | |
| Secondary | TTD in Cough Score (Item 31) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | TTD in the score of EORTC QLQ-C13 Item 31 will be presented. The EORTC QLQ-C13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Have you coughed?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates more frequent coughing. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 40 months | |
| Secondary | TTD in Chest Pain Score (Item 40) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | TTD in the score of EORTC QLQ-C13 Item 40 will be presented. The EORTC QLQ-C13 is a lung cancer specific health-related quality-of life (QoL) questionnaire. Participant response to the question "Have you had pain in your chest?" is scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a worse level of chest pain. TTD is defined as the time to first onset of 10 or more (out of 100) deterioration from baseline and confirmed by a second adjacent 10 or more deterioration from baseline. | Up to approximately 40 months | |
| Secondary | Number of Participants Who Experienced One or More Adverse Events (AEs) | The number of participants who experienced an adverse event (AE) will be presented. An AE is defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. | Up to approximately 40 months | |
| Secondary | Number of Participants Who Discontinued Study Intervention Due to an AE | The number of participants who discontinue study intervention due to an adverse event (AE) will be presented. An AE is defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. | Up to approximately 40 months | |
| Secondary | Duration of Response (DOR) | For participants who demonstrate a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by blinded independent central review will be presented. | Up to approximately 40 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05985330 -
Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
|
||
| Recruiting |
NCT05013450 -
Dupilumab_Metastatic NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05984277 -
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
|
Phase 3 | |
| Completed |
NCT03215810 -
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT05675683 -
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
|
||
| Active, not recruiting |
NCT02411448 -
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
|
Phase 3 | |
| Recruiting |
NCT04410796 -
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
|
Phase 2 | |
| Recruiting |
NCT03300115 -
Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
|
Phase 2 | |
| Recruiting |
NCT05635708 -
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03265080 -
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
|
Phase 1 | |
| Withdrawn |
NCT02639234 -
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05364073 -
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
|
Phase 1 | |
| Completed |
NCT03926260 -
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
|
N/A | |
| Active, not recruiting |
NCT03976375 -
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
|
Phase 3 | |
| Recruiting |
NCT05546905 -
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
|
||
| Withdrawn |
NCT01936961 -
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
|
N/A | |
| Active, not recruiting |
NCT06212752 -
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
|
Phase 3 | |
| Recruiting |
NCT05607550 -
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
|
Phase 3 | |
| Recruiting |
NCT03976856 -
Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
|
Phase 1 |